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Introduction
Limb-girdle muscular dystrophies (LGMD) include almost 30 different monogenic diseases characterized 
by progressive weakness and atrophy presenting in the shoulder and pelvic girdle muscles. The total preva-
lence is 2.19 per 100,000 (95% CI, 1.78–2.70) (1). There is no therapy. One of  the most severe and frequent 
types is caused by α-sarcoglycan deficiency due to mutations in SGCA (classified as LGMD2D or LGM-
DR3). Affected patients become increasingly week in the late first decade of  life and often become wheel-
chair-bound during puberty. Cardiac and respiratory involvement are possible. SGCA has 9 coding exons 
and is expressed in striated muscle (2, 3). Disease-causing mutations are spread along the entire length of  
the gene without defined mutational hot spots (4, 5). However, some mutations like c.157G>A have been 
reported more frequently (6, 7). α-Sarcoglycan is a 50 kDa transmembrane protein, part of  the sarcoglycan 
complex and the dystrophin-associated protein complex (DAPC) (2, 3). The DAPC protects muscle fibers 
from mechanical stress, and its dysfunction leads to various forms of  muscular dystrophy (MD) (8, 9).
Muscle fibers are syncytial structures with postmitotic nuclei formed by the fusion of  myogenic pro-
genitor cells, called myoblasts, during prenatal and postnatal development. Skeletal muscle can regener-
ate from muscle stem cells (MuSC), also called satellite cells, a pool of  tissue-specific stem cells located 
between the muscle fiber membrane (sarcolemma) and the basal lamina that surrounds every fiber (10). In 
healthy muscle, satellite cells are quiescent or slow cycling. When activated in response to severe damage, 
they extensively proliferate and give rise to large numbers of  myoblasts that fuse to damaged myofibers or 
to one another to generate new myofibers (11). Skeletal muscle regeneration cannot occur without satellite 
cells (12, 13). Patients with MD suffer constant tissue degeneration, which prompts satellite cells to be 
constantly activated, leading to satellite cell exhaustion, regenerative deficit, and replacement of  muscle by 
fat and connective tissue (14, 15).
Cell replacement therapies with well-defined and highly myogenic cell populations could represent 
a safe and long-term treatment avenue for MD patients (16); however, MuSC are scarce and difficult to 
Skeletal muscle can regenerate from muscle stem cells and their myogenic precursor cell progeny, 
myoblasts. However, precise gene editing in human muscle stem cells for autologous cell 
replacement therapies of untreatable genetic muscle diseases has not yet been reported. Loss-of-
function mutations in SGCA, encoding α-sarcoglycan, cause limb-girdle muscular dystrophy 2D/
R3, an early-onset, severe, and rapidly progressive form of muscular dystrophy affecting both male 
and female patients. Patients suffer from muscle degeneration and atrophy affecting the limbs, 
respiratory muscles, and heart. We isolated human muscle stem cells from 2 donors, with the 
common SGCA c.157G>A mutation affecting the last coding nucleotide of exon 2. We found that 
c.157G>A is an exonic splicing mutation that induces skipping of 2 coregulated exons. Using adenine 
base editing, we corrected the mutation in the cells from both donors with > 90% efficiency, thereby 
rescuing the splicing defect and α-sarcoglycan expression. Base-edited patient cells regenerated 
muscle and contributed to the Pax7+ satellite cell compartment in vivo in mouse xenografts. Here, 
we provide the first evidence to our knowledge that autologous gene–repaired human muscle stem 
cells can be harnessed for cell replacement therapies of muscular dystrophies.
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manipulate ex vivo. In addition, skeletal muscle is the most abundant tissue in the body; therefore, devel-
oping cell replacement therapies for MD patients poses substantial challenges. We have previously shown 
that MuSC can be isolated and substantially expanded from human muscle biopsy specimens and that they 
maintain in vivo regenerative capacity in xenograft models (17, 18). Using them in an autologous setting for 
MD patients would require correcting the genetic defect before reimplantation.
Precise and efficient gene repair in primary somatic stem and progenitor cells ex vivo is increasingly 
plausible due to the rapid development of  CRISPR/Cas9-based tools for base editing that are independent 
from the cellular DNA repair pathway choice. Adenine base editing (ABE) enables the precise targeted 
conversion of  adenine into guanine nucleotides without inducing DNA double-strand breaks (19). An ABE 
consists of  a catalytically impaired Cas9 in fusion with an adenine deaminase enzyme (TadA) that converts 
adenine into inosine on the single-stranded DNA bubble created by Cas9 binding to a target site. Inosine 
is subsequently replaced by guanine. To be accessible to the deaminase, the target adenine must be located 
at a defined distance from the protospacer adjacent motif  (PAM), the so-called ABE activity window (19). 
Because of  its predictable outcome, high precision and reduced off-target effects (20, 21), ABE is potentially 
the safest gene editing tool to date. However, despite technical advances in tool development, therapeutic 
gene or base editing in clinically relevant human MuSC has not yet been reported.
Here, we found a potentially new pathomechanism for a loss-of-function SGCA c.157G>A mutation 
and corrected it with > 90% efficiency in primary MuSC from a LGMD2D patient and a related carrier 
using ABE, without detectable editing at predicted off-target loci. ABE-corrected patient MuSC function-
ally engrafted and reconstituted the satellite cell compartment following intramuscular transplantation in a 
xenograft model. We hereby provide the first evidence to our knowledge that primary human MuSC can be 
efficiently and safely gene edited and harnessed for autologous cell replacement therapies of  MD.
Results
Isolation of  primary MuSC from a patient and a carrier with a compound heterozygous SGCA c.157G>A mutation. We 
isolated and characterized primary MuSC from muscle biopsy specimens obtained from a 10-year-old male 
LGMD2D patient carrying a compound heterozygous SGCA c.157G>A mutation and from a related carrier 
(Figure 1, A–D). Primary MuSC cultures from patient and carrier were 95%–100% Desmin+ and expressed 
the myogenic markers Pax7, MyoD, and Myf5 and the proliferation marker Ki-67 (Figure 1, A and B). The 
c.157G>A mutation affects the last coding nucleotide of  exon 2 (Figure 1, C and D). Our patient has a second 
heterozygous loss-of-function SGCA mutation (c.748-2A>G) in the splice acceptor of  exon 7 (Figure 1C). 
We also obtained primary MuSC from a related carrier of  the c.748-2A>G mutation (Supplemental Figure 
1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.145994DS1).
SGCA c.157G>A is an exonic splicing mutation. SGCA c.157G>A has been reported as a missense variant 
(p.Ala53Thr) (6, 7), but its consequences on mRNA level were not investigated. We analyzed the SGCA 
mRNA and found 2 smaller bands corresponding to the skipping of  exon 2 alone or exons 2 and 3 in the 
heterozygous c.157G>A carrier (Figure 2, A and B). No c.157A was detectable in the band corresponding 
to the full-length mRNA, indicating that residual inclusion of  the mutant exon 2 is negligible (Supplemental 
Figure 2A; see complete unedited blots in the supplemental material). Splicing of  exons 4–9 was unaffected 
(Supplemental Figure 2B). Overall, there was no significant difference in the relative SGCA mRNA levels 
between carrier and controls (Figure 2C). We then analyzed the predicted strength of  the 5′ splice site of  
SGCA exon 2 using MaxEntScan:score5ss (22). We found that the mutation strongly decreases the strength 
of  the 5′ splice site (Figure 2D). These results indicate that SGCA c.157G>A is an exonic splicing mutation. 
To better understand the mechanism underlying the codependent splicing of  exons 2 and 3, we 
designed SGCA WT and c.157G>A minigene constructs covering exons 1–4 and the interjacent introns 
1–3 (Figure 2E). Splice sites can be recognized by the spliceosome in a cross-intron complex (intron defi-
nition) or in a cross-exon complex (exon definition). Exon definition happens if  exons are flanked by long 
introns, as is the case for most human exons, and the initial exon-defined complex must be transferred into 
an intron-defined complex for productive splicing. SGCA exons 2 and 3 are separated by a short intron of  
94 nt. Splice-site recognition for short introns (<200–250 nt) occurs via the intron definition pathway and 
is more efficient, resulting in enhanced inclusion of  exons with weak splice sites (23). Thus, we reasoned 
that the short length of  intron 2 could contribute to the efficient splicing of  both exons 2 and 3. Extending 
the length of  intron 2 should induce a switch from intron to exon definition, thereby reducing the efficiency 
of  exon 2 and 3 splicing and making exon 3 inclusion independent of  the c.157G>A mutation. To test this 
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hypothesis, we additionally created minigene constructs where intron 2 was extended by 498 nt using a low 
complexity intronic sequence from the human β-globin gene (Figure 2E).
We analyzed splicing of  these minigenes in HEK293T cells and observed similar patterns for the WT 
and c.157G>A SGCA constructs as observed in human muscle tissue from controls or the heterozygous 
carrier, respectively (Figure 2, F and G; Supplemental Figure 2C; and Supplemental Figure 3). The full-
length mRNA isoform including exons 1–4 was completely abolished by the c.157G>A mutation, which 
resulted in skipping of  exon 2 alone or, more frequently, in skipping of  exons 2 and 3. Consistent with our 
model, extending intron 2 induced exon 2 skipping independently of  the c.157G>A mutation, which was 
frequently accompanied by exon 3 skipping. A weak cryptic splice site within the extended intron was 
Figure 1. Characterization of primary MuSC from 2 donors with a heterozygous SGCA c.157G>A mutation. (A and B) Immunostaining for the satellite cell 
marker Pax7; the myogenic markers Desmin, MyoD, and Myf5; and the proliferation marker Ki-67 in patient (A) and carrier (B) primary MuSC cultures. The 
percentage of cells expressing each marker is displayed on the images in the corresponding colors. Nuclei were counterstained with Hoechst. At least 100 
nuclei were counted per sample, and staining was done before cryopreservation and after thawing. (C) SGCA sequence analysis from the patient shows the 
compound heterozygous mutation in exon 2 (c.157G>A) and the splice acceptor of exon 7 (c.748-2A>G). (D) SGCA sequence analysis from the carrier shows 
the compound heterozygous mutations in exon 2 (c.157G>A) and a homozygous WT exon 7 sequence. Scale bars: 50 μm.
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Figure 2. SGCA c.157G>A is an exonic splicing mutation. (A) RT-PCR analysis of SGCA mRNA in muscle tissue from controls and the c.157G>A carrier. Primer 
binding sites and expected band sizes are displayed in the panel above. Control 3 is a heterozygous SGCA c.748-2A>G carrier with a WT SGCA exon 2 sequence. 
The RT-PCR was performed 3 times. (B) Sequencing of the bands from A shows skipping of exon 2 or exon 2+3 in the c.157G>A carrier. (C) qPCR analysis of SGCA 
mRNA in muscle tissue from controls and the c.157G>A carrier using primers against the exon 1–2 or exon 6–7 boundaries. Control 3 is represented by a green 
square. The qPCR was performed in technical triplicates. Values were normalized to GAPDH and relativized to the mean of controls. (D) Strength scores of the 
SGCA exon 2 splice donor for the WT and the mutant sequence predicted by MaxEntScan:score5ss. (E) Minigene construct schemes. FL, full-length SGCA exon 
1–4 (blue boxes) with the intermediate introns (black lines); +498, a 498 bp-long low complexity intronic sequence from the human HBB gene (yellow) was 
inserted to extend intron 2. The size of each intron is indicated above in gray. For intron 2, the size before and after the branch point is indicated below in gray. 
UT, untransfected; EV, empty vector; WT, WT SGCA; G>A, c.157G>A mutation. (F) Minigene splicing patterns in HEK293T cells analyzed by low-cycle RT-PCR with 
a 32P-labeled forward primer; products were separated by denaturing PAGE. The splice isoforms identified are shown on the right (identity confirmed by Sanger 
sequencing). *, intron-retention isoforms; 2*, truncated exon 2 (40 nt); 3*, truncated exon 3 (–70 nt). (G) Splice isoform quantification from F using Phosphorim-
ager analysis. Quantified values are presented as mean ± SD (n = 3). E, exon; I, intron.
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occasionally selected, resulting in the inclusion of  exon 3 and a segment of  intron 2 (Figure 2, F and G, 
and Supplemental Figure 3). These splicing patterns suggest that intron definition of  the short intron 2 is 
required for the correct recognition of  both exons 2 and 3, and they provide a mechanistic explanation for 
the effect of  the c.157G>A mutation on exon 3 splicing.
ABE corrects the SGCA c.157G>A mutation in patient-derived induced pluripotent stem cells. To work out 
strategies to genetically correct the c.157G>A mutation, we generated induced pluripotent stem cells 
(iPSC) from the patient (Supplemental Figure 4). We identified c.157G>A as an ideal ABE target, since 
it is located 15 bp upstream of  an –NGG PAM (equivalent to protospacer position 6, thus in the center of  
the ABE activity window). No other adenines are located within the ABE activity window, so undesired 
bystander edits are unlikely (Figure 3A). We first assessed if  ABE can be used to repair the c.157G>A 
mutation in patient iPSC. We transfected these cells with a plasmid encoding ABE7.10_4.1, a vector 
based on ABE7.10 (19) containing a codon-optimized Cas9 (D10A) nickase N-terminally fused to the 
TadA heterodimer, followed by a T2A-Venus cassette under control of  the CAG promoter, and an sgRNA 
expression cassette. We enriched for Venus+ cells via FACS (Figure 3B and Supplemental Figure 5B) and 
assessed ABE efficiency using EditR (24). We found that ABE7.10_4.1 induced efficient c.157A>G con-
version when combined with a suitable gRNA (gRNA#1), without any detectable bystander A>G edits 
(Figure 3, C and D, and Supplemental Figure 6). We additionally examined the ability of  the enhanced 
specificity Cas9 variant eSpCas9(1.1) (25), fused to the TadA heterodimer in an identical configuration 
(ABE7.10_3.1), to induce A>G conversions at this locus but detected only minimal editing. We thus 
selected ABE7.10_4.1 for further experiments.
Figure 3. ABE corrects the SGCA c.157G>A mutation in patient-derived iPSC. (A) c.157G>A is located in the center of the ABE activity window for gRNA#1. 
(B) Experimental design. A plasmid encoding ABE7.10_4.1 or ABE7.10_3.1 was transfected into patient iPSC. Venus+ cells were selected via FACS, and the 
bulk sorted population was analyzed. (C) EditR analysis of nucleotide rates at each protospacer position in patient iPSC transfected with ABE7.10_4.1 and 
_3.1 in combination with gRNA#1. iPSC transfected with ABE7.10_4.1 without gRNA are shown as control. (D) c.157G/A nucleotide rates from EditR analysis. 
Quantified values are presented as mean ± SD (n = 5). Statistical analysis of the difference in c.157G nucleotide rates (light blue) between the columns was 
performed using the Mann-Whitney U test. Two-tailed P values were calculated. *P < 0.02; **P < 0.01.
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ABE results in > 90% correction of  SGCA c.157G>A in primary human MuSC without detectable off-target edit-
ing. We next asked if  ABE could efficiently repair the c.157G>A mutation and rescue the phenotype in 
human primary MuSC. We transfected MuSC from the patient and the heterozygous carrier with various 
concentrations of  the ABE7.10_4.1/gRNA#1 vector, as above, and enriched for Venus+ cells (Figure 4A and 
Supplemental Figure 5A). Following sorting, we expanded the Venus+ cells in culture and analyzed on- and 
off-target editing. All vector concentrations resulted in > 99% c.157G nucleotide rates in patient and carrier 
MuSC as analyzed by EditR (Figure 4B). We then performed amplicon sequencing with subsequent analysis 
by CRISPResso2 (26) and confirmed high c.157G nucleotide rates of  > 90% for patient MuSC and > 85% 
for carrier MuSC (Figure 4C, Supplemental Figure 7, and Supplemental Figure 8). Bystander A>G editing 
at protospacer position 10 was detected in a very low (0.2%–2%) percentage of  reads. In 2 samples, we 
detected 1.1% and 0.3% of  reads containing indels. Omission of  gRNA did not result in either A>G editing 
or indels (Figure 4C, Supplemental Figure 7, and Supplemental Figure 8). To rule out allele-detection bias, 
Figure 4. ABE repairs the SGCA c.157G>A mutation in patient and carrier primary MuSC without 
detectable off-target editing. (A) Experimental design. Primary MuSC from the patient and the car-
rier were transfected with ABE7.10_4.1/gRNA#1 or without gRNA. FACS was performed to enrich for 
Venus+ cells, which were subsequently analyzed. (B) EditR analysis of nucleotide rates at each pro-
tospacer in patient MuSC transfected with ABE7.10_4.1/gRNA#1. (C) Percentage of reads containing 
c.157G/A, bystander editing of A10, and indels in patient and carrier MuSC transfected with a range of 
ABE7.10_4.1/gRNA#1 vector concentrations. (D) A SNP located 332 bp downstream of the mutation 
and heterozygous in the patient was included in the amplicon to rule out allele detection bias. The 
plot shows the percentage of reads aligned to each allele. (E) Amplicon sequencing analysis of the 4 
predicted exonic off-target sites. Amplicon sequencing data were analyzed using CRISPResso2.
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we designed a PCR amplicon that includes a heterozygous single nucleotide polymorphism (SNP) located 
332 bp downstream of  c.157G>A in the patient SGCA gene (SNP ID: rs2696297). We confirmed an equal 
representation of  both alleles in our amplicon sequencing data, thus ruling out detection bias (Figure 4D). 
This analysis was not possible for the carrier MuSC, where this SNP is homozygous. We next aimed to 
characterize the off-target profile of  our editing approach. We investigated the 4 predicted exonic off-target 
sites that contain adenines within the ABE activity window via amplicon sequencing and CRISPResso2 
analysis. We could not detect any Cas9-dependent off-target editing events at these loci with either the low-
est or highest vector concentration (Figure 4E, Supplemental Figure 9, and Supplemental Figure 10). Our 
detection threshold for reads containing off-target events ranged from 0.01% for the locus with the lowest 
number of  aligned reads per sample (ZNF571; Supplemental Figure 10A) to 0.0004% for the locus with the 
highest number of  aligned reads per sample (KIF1A; Supplemental Figure 10B). We thus have concluded 
that the SGCA c.157G>A mutation can be repaired in human primary MuSC with very high efficiency and 
specificity via ABE. Repaired SGCA c.157G>A is hereafter referred to as SGCA c.157Grep.
SGCA c.157Grep primary MuSC show normal α-sarcoglycan mRNA and protein expression. To assess the func-
tional outcome of  ABE, we analyzed α-sarcoglycan mRNA and protein expression in SGCA c.157Grep myo-
tubes. We found that the splicing defect was rescued as shown by the increase in α-sarcoglycan transcripts 
containing exon 2 in SGCA c.157Grep compared with unedited patient and carrier myotubes, reaching levels 
similar to control 3 (heterozygous c.748-2A>G carrier) in the case of  patient myotubes (Figure 5A). Further-
more, total SGCA mRNA levels increased in patient myotubes following ABE (Figure 5A), probably because 
coskipping of  exons 2 and 3 (but not exon 2 alone) induces a frameshift, leading to a premature stop codon, 
which could result in nonsense-mediated mRNA decay (NMD). Western blot and immunostaining analysis 
revealed that α-sarcoglycan protein was restored in SGCA c.157Grep patient cells (Figure 5, B and E).
SGCA c.157Grep primary patient MuSC are viable, proliferative, and myogenic. Primary cells are especially sus-
ceptible to stress induced by extensive manipulation. Primary MuSC derived from MD patients with muta-
tions in genes responsible for membrane integrity are particularly vulnerable. We observed a decrease in cell 
proliferation in the first days following transfection and sorting as compared with untransfected patient MuSC. 
However, Venus+ cells (≥48% of the source cell population; Supplemental Figure 5A) proliferated extensively 
after sorting and were further expanded for at least 2–3 passages before cryopreservation. Samples for on- and 
off-target editing analysis were collected at this time point. We assessed Desmin, Pax7, MyoD, Myf5, and Ki-67 
expression in all SGCA c.157Grep patient MuSC populations at the time of cryopreservation. We found that, in 
unedited patient MuSC, the percentage of Desmin– cells increased with the passages up to approximately 11%. 
All but 1 SGCA c.157Grep patient MuSC populations had > 98% Desmin+ cells. Myogenic marker expression 
was comparable in SGCA c.157Grep pure MuSC populations and passage-matched unedited patient MuSC 
(Figure 5C and Supplemental Table 1). SGCA c.157Grep MuSC were recovered and further expanded for 
1 passage before transplantation, at which time the expression of myogenic and proliferation markers was 
reassessed. The percentage of cells positive for those markers was maintained (Supplemental Table 1). SGCA 
c.157Grep primary MuSC could readily fuse into multinucleated myotubes in vitro (Figure 5D). Moreover, the 
pattern of α-sarcoglycan localization was indistinguishable from control myotubes (Figure 5E).
SGCA c.157Grep primary MuSC regenerate muscle and repopulate the satellite cell niche in vivo. We next asked if  
SGCA c.157Grep primary MuSC would contribute to muscle regeneration in vivo. We, thus, transplanted them 
into irradiated anterior tibial muscles of immunocompromised NSG mice. We found that SGCA c.157Grep 
patient MuSC gave rise to human muscle fibers (Figure 6, A–C) that expressed α-sarcoglycan (Figure 6D and 
Supplemental Figure 11). Furthermore, the satellite cell niche between the sarcolemma and the basal lamina was 
populated with numerous Pax7+ cells of human origin (Figure 6E). Taken together, SGCA c.157Grep patient 
MuSC are capable of both myofiber regeneration and reconstitution of the satellite cell compartment in vivo.
Discussion
Therapeutic gene editing in muscular dystrophies is developing into a realistic scenario. The exact treat-
ment regimen will depend on the affected muscles, the diseased gene, and the type of  mutation. Gene 
supplementation therapy using adeno-associated viral (AAV) vectors may be suitable for genes up to a cer-
tain size. However, the exogenously provided cDNA is not physiologically regulated in terms of  splicing 
and spaciotemporal expression and poses a risk of  insertional mutagenesis. AAV-mediated CRISPR/Cas9 
delivery directly into the muscle has enabled highly efficient in vivo gene editing in Duchenne muscular 
dystrophy (DMD) mice and large animals models (27–30), and it could potentially reach and permanently 
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repair a very large fraction of  myonuclei. In vivo ABE in muscle has been achieved in a DMD mouse 
model (31). However, if  not done before substantial degeneration, fatty-fibrous replacement, or satellite 
cell exhaustion have occurred, the disease course may not be reversible. In addition, liver toxicity associ-
ated with systemic AAV administration has resulted in fatal complications in some patients who received 
the highest viral dose in a gene supplementation clinical trial for myotubular myopathy, calling for very 
cautious planning in future trials of  systemic AAV administration (32). All of  this has put stem cell thera-
pies back on stage in the treatment of  muscular dystrophies (16).
We, for the first time to our knowledge, demonstrate here highly efficient and precise correction of  
a MD-causing mutation in primary patient MuSC using ABE. The edited cells maintain their ability to 
Figure 5. SGCA c.157Grep patient MuSC express α-sarcoglycan, and they are viable and myogenic. (A) qPCR analysis of SGCA mRNA in SGCA c.157Grep 
compared with unedited (U) patient and carrier myotubes. Values are normalized to GAPDH and relativized to control 3. SGCA mRNA values were additional-
ly normalized to MYH2 to correct for differences in the differentiation stage of the cells, which may affect promoter activity. Each data point represents the 
mean ± SD for the n = 3 technical replicates of each biological sample. (B) Western blot analysis of α-sarcoglycan protein in SGCA c.157Grep patient myotubes 
compared with unedited (U) patient and control 3 myotubes. Myosin heavy chain (MyHC) was used as a differentiation marker. Vinculin and GAPDH were 
used as loading controls. The intensity of α-sarcoglycan Western blot bands was quantified using ImageJ and normalized to Vinculin and MyHC. (C) SGCA 
c.157Grep patient MuSC were immunostained for Pax7, Desmin, MyoD, Myf5, and Ki-67. The analysis was performed for all SGCA c.157Grep patient cell 
populations, and a quantification is shown in Supplemental Table 1. (D) SGCA c.157Grep MuSC readily fused into multinucleated myotubes expressing MyHC. 
The analysis was performed for all SGCA c.157Grep patient cell populations. (E) α-Sarcoglycan immunostaining in control myotubes, as well as unedited and 
SGCA c.157Grep patient myotubes. The analysis was performed for all SGCA c.157Grep patient cell populations. MT, myotubes. Scale bars: 50 μm.
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produce new muscle fibers and repopulate the Pax7+ stem cell pool in vivo as shown previously for healthy 
human MuSC (17, 18). These cells are transplantable in an autologous setting with a small and calculable 
risk, and the repaired gene sequence maintains the endogenous regulation machinery in place. Although 
the availability of  primary human MuSC in early passages and with high regenerative capacity is limited, 
this should not preclude further developments for several reasons. First, minimizing stress during gene 
repair and cell expansion to obtain large numbers of  repaired cells is a challenging but solvable problem. 
Human MuSC expansion on improved scaffolds has resulted in high proliferation rates (33), and culturing 
human MuSC in niche-like environments has been shown to enhance their engraftment potential (17, 34). 
In the case of  MD patients, the time at which the muscle biopsy for MuSC isolation is obtained may be 
crucial and should be carefully considered. Second, although protocols to differentiate iPSC into cells with 
Figure 6. SGCA c.157Grep patient MuSC regenerate muscle in vivo. (A) SGCA c.157Grep patient MuSC were injected into preirradiated anterior tibial muscles 
of immunocompromised NSG mice. Grafted muscles were collected for analysis after 19 days. (A and B) Grafted muscles were immunostained with antibodies 
that specifically recognize human Lamin A/C and human Spectrin, labeling donor nuclei and donor-derived myofibers, respectively. In total, 31–87 human 
nuclei and 33–72 human myofibers were found per section (n = 2). (C) Grafted muscles were immunostained with antibodies against human Lamin A/C and 
Desmin. (D) Grafted muscles were immunostained with antibodies against human Spectrin and α-sarcoglycan. (E) Grafted muscles were immunostained with 
antibodies against human Lamin A/C, Pax7, and Laminin to identify satellite cells of human origin located in the stem cell niche under the basal lamina (n = 
2). Human Pax7+ satellite cells are indicated by arrows. Nuclei were counterstained with Hoechst. Scale bars: 100 μm (A), 50 μm (B), 20 μm (C and D), 5 μm (E).
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myogenic potential in xenograft models have been developed (35, 36, 37), the derived cells so far lack purity 
and maturity. Nevertheless, iPSC-derived myogenic cells have successfully been used to model LGMD 2D/
R3 in vitro (38) and could become a relevant source for cell replacement therapies in the future, provided 
that their safety and efficacy profile matches the requirements for clinical use. Third, the reconstitution 
of  single muscles that could be achieved with limited cell numbers may well result in improved patient 
autonomy and life quality. Examples would be transplantation into finger flexors, resulting in improved 
grip strength or restored strength of  respiratory muscles, such as the diaphragm. Similarly, swallowing 
function was improved in oculopharyngeal muscular dystrophy (OPMD) patients following transplanta-
tion of  autologous nongenetically corrected myoblasts into the pharyngeal muscles. However, a long-term 
therapeutic effect would likely require transplanting gene-corrected autologous MuSC (39).
Compared with classical CRISPR/Cas9-based approaches that rely on the cellular DNA repair machin-
ery to install edits, base editing does not require DNA double-strand breaks and has a predictable, well- 
defined, and precise repair outcome (19). It is also cell-cycle independent and, thus, suitable for editing in 
postmitotic syncytial myonuclei and MuSC. Sequence restrictions like PAM requirements and the presence of  
other editable nucleotides in the activity window currently limit the scope of  base editors. However, the fast- 
expanding landscape of  new Cas enzymes with widened PAM specificities and the latest generation deami-
nase domains (40–42) are rapidly widening the spectrum of mutations amenable to base editing. A question 
that remains open is how to reconcile faster kinetics and wider editing scopes with safe off-target profiles, espe-
cially for therapeutic applications. Here, we used ABE7.10, which has been shown to produce minimal Cas9- 
dependent or -independent DNA and RNA off-target editing in vitro and in vivo (20, 21, 40, 41). Bystander 
A>G editing at protospacer position 10 was detectable in SGCA c.157Grep MuSC, albeit at very low levels. Its 
functional consequences are difficult to predict because this adenine is in intron 2. Notably, another MD-caus-
ing SGCA G>A mutation is located just 1 nucleotide downstream (c.157+1G>A) (5, 43), within the same 
ABE activity window as shown here, and it could presumably be corrected with an almost identical approach.
We could not detect ABE-induced Cas9–dependent editing at any of  the predicted exonic off-target 
loci. For the gRNA used in this study, all predicted off-target sites have at least 3–4 mismatches to the target 
sequence. Furthermore, all off-target sites except 1 contain several mismatches within the seed sequence 
(nucleotides 1–12 proximal to the PAM), which makes them unlike targets for Cas9 binding. While we 
cannot rule out Cas9-dependent or -independent off-target editing in other loci, we found no evidence of  
malignant proliferation of  SGCA c.157Grep MuSC in vitro or following transplantation into NSG mice. 
For therapeutic purposes, we propose a targeted analysis of  predicted off-target sites, proto-oncogenes, and 
tumor-suppressor genes. Whole genome sequencing could reveal off-target events in unpredicted loci, but 
low-frequency sequence alterations may be difficult to detect.
Although most proof-of-concept gene editing studies focus on homozygous mutations or X-linked dis-
eases like DMD, we argue that this is hardly a realistic scenario for diseases like LGMD, where the vast 
majority of  patients have heterozygous mutations (5). In patients with autosomal recessive LGMD, repair-
ing 1 allele would convert the cells into a carrier-like genotype, thus effectively restoring the phenotype. 
Most patients with > 30% α-sarcoglycan levels remain ambulant until age 60 as opposed to < 20 years for 
patients with completely absent protein (5), evidencing that increasing the levels of  α-sarcoglycan in the 
muscle to even less than 50% could dramatically slow down disease progression.
A particular challenge of  repairing heterozygous mutations, whereby the repaired sequence is identical 
to the WT sequence, is potential allele detection bias resulting in a wrong interpretation of  gene editing out-
comes (44, 45). Although ABE requires that only 1 DNA strand is nicked, large indels that interfere with 
primer binding sites cannot be excluded and may be especially relevant in the context of  therapeutic cell 
products. Here, we have included a heterozygous SNP in the same amplicon as the edit to unequivocally 
rule out an unbalanced allele representation in our data set.
For all monogenic diseases like MD, understanding the pathomechanism of  disease-associated vari-
ants is crucial for proper patient stratification and to administer or develop the right therapies. Numerous 
MD-causing mutations classified as missense result in complete loss of  protein. SGCA c.157G>A was ini-
tially described as a loss-of-function missense variant leading to a complete absence of  α-sarcoglycan (6, 7). 
Here, we describe a splicing defect as the main consequence of  this mutation. Although it does not disrupt 
the reading frame, exon 2 skipping removes > 10% of  the SGCA coding sequence. An intriguing finding is 
the coskipping of  exons 2 and 3, which is enhanced by the mutation and induces a frameshift. We suggest 
that recognition of  the short SGCA intron 2 by the spliceosome through the intron definition pathway serves 
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as a mechanism to promote the coregulated inclusion of  exons 2 and 3. This conclusion is based on our 
finding that impairment of  intron recognition induced by the c.157G>A mutation or extension of  the intron 
abolishes exon 2 and significantly reduces exon 3 inclusion.
It is becoming increasingly clear that exonic mutations that affect splicing are often incorrectly stratified 
as missense variants (46, 47). A more comprehensive analysis of  such variants will be pivotal to understand 
their functional outcome, shed new light into the mechanisms of  mRNA splicing, and uncover mutations 
addressable by approved splice modulating therapies like exon skipping. This may be especially relevant for 
large genes like DMD or DYSF, where removal of  1 or several exons can result in a truncated yet partially 
functional protein (48, 49) and could rescue a frameshift induced by aberrant exon exclusion.
In summary, we provide the first evidence to our knowledge that gene-edited human primary MuSC 
can be harnessed and are a promising and safe source for autologous cell replacement therapies of  MD. 
Routine generation of  gene-repaired primary MuSC to use in a clinical setting will require adapting the 
gene delivery methods and developing pipelines for systematic off-target profiling and biosafety testing. 
Transient ex vivo ABE expression would evade possible complications associated with preexisting immu-
nity against Cas9 (50). Whether restoring α-sarcoglycan could elicit an immune response requires further 
investigation. Despite the concerns raised so far for systemic AAV administration, in vivo gene editing 
has the unique potential of  targeting all muscles throughout the body. Provided that further developments 
guarantee an acceptable risk profile, the benefits might well outweigh the drawbacks. We can, thus, envision 
future treatments for MD patients combining in vivo gene editing to target the majority of  myofibers in 
affected muscles, as well as cell-based therapies with autologous gene corrected MuSC to ensure a long-
term muscle homeostasis by gene repaired muscle stem and progenitor cells. As of  now, cell replacement 
therapies with gene corrected autologous MuSC to restore function in a subset of  critical muscles are reach-
able, are potentially safe, and could substantially improve patients’ life quality and autonomy.
Methods
Patients. Primary MuSC were generated from a 13-year-old male patient with MD due to compound het-
erozygous mutations in SGCA, c.157G>A and c.748-2A>G. The patient has limb girdle weakness but no 
cardiac failure. Both parents (carriers) are clinically unaffected. All family members are of  White. There is 
1 sister who is also affected.
Primary MuSC isolation and culture. Immediately after the biopsy procedure, the muscle specimen was 
transferred into Solution A for transport (30 mM HEPES, 130 mM NaCl, 3 mM KCl, 10 mM D-glucose, 
and 3.2 μM Phenol red, pH 7.6; Carl Roth). The fresh muscle specimen was manually dissected, and frag-
ments were subjected to hypothermic treatment at 4°C–6°C for 2–7 days prior to downstream processing 
for MuSC isolation (17, 18). Oligoclonal MuSC colonies were obtained following mechanical dissection as 
described (18). The outgrowing colonies were expanded until passage 4 and characterized prior to cryopres-
ervation. To enhance the probability of  available MuSC in difficult-to-handle biopsy specimens, classical 
purification was performed in parallel (14). All cell populations used in this study were ≥ 95% positive for 
Desmin. To induce myoblast-to-myotube fusion, medium was switched to Opti-MEM I Reduced Serum 
Media (Thermo Fisher Scientific) once cells reached confluence.
iPSC generation and characterization. Patient iPSC were generated and characterized as described (51). 
Reagents are listed in Supplemental Table 3. iPSC are available in the Human Pluripotent Stem Cell Registry 
(hPSCreg; https://hpscreg.eu/cell-line/MDCi017-A) under the cell line identifier MDCi017-A. The hiPSC 
line with the homozygous c.157G>A mutation was identified in an experiment targeting the SGCA locus 
with CRISPR/Cas9, followed by clonal selection, PCR, and Sanger sequencing to confirm the sequence and 
zygosity. Based on the SNP signature of  both alleles along the entire SGCA locus, the homozygous c.157G>A 
mutation likely results from loss of  heterozygosity (LOH) due to an interhomologous recombination event.
Minigene cloning. SGCA exons 1–4 were amplified from patient or control gDNA. For extension of  intron 
2, the minigene was amplified in 2 parts using additional primers positioned within intron 2. Approximately 
500 bp of  the human HBB (β-globin) intron 2 were amplified from genomic DNA and joined between the 2 
segments of  the minigene. All constructs were cloned into pcDNA3.1 digested with HindIII and XhoI. Pos-
itive colonies were verified by test digest and Sanger sequencing. Primers are listed in Supplemental Table 2.
Minigene splicing assay. Minigenes were transfected into HEK293T cells using Roti-Fect, and cells were 
harvested after 48 hours. RNA was extracted using RNATri (Bio&Sell), and genomic/plasmid DNA was 
eliminated via DNaseI digest. RNA (1 μg) was used in a plasmid-specific reverse transcription (RT) reaction. 
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The minigene was analyzed using plasmid-specific primers (Supplemental Table 2) upstream and downstream 
of the inserts in a standard PCR reaction. The obtained products were resolved on a 2% agarose gel. Low-cy-
cle PCR was performed with a 32P-labeled forward primer, and the products were separated by denaturing 
PAGE. Bands were visualized with a Phosphoimager and quantified using ImageQuantTL. Quantifications 
are presented as mean ± SD (n = 3).
ABE plasmids. A plasmid (HE_p4.1) containing a mammalian codon-optimized CAG-driven S. pyogenes 
Cas9 (SpCas9) with a double C-terminal nuclear localization signal (52), followed by a T2A-Venus cassette 
plus a human U6 promoter–driven sgRNA scaffold, was assembled as follows: Cas9-Venus from pU6chim-
RNA-CAG-Cas9-venus-bpA_(oriA) (Addgene, 86986) was exchanged for Cas9-T2A-Venus from pCAG-
Cas9v2T2A-venus-T2A-Kk-bpA (Ralf  Kühn lab). Plasmid pCAG-Cas9v2T2A-venus-T2A-Kk-bpA was 
generated by Gibson assembly from plasmid pCAG-Cas9v2T2A-venus-bpA (Ralf  Kühn lab), opened with 
BsrGI and MluI, and a PCR fragment for the insertion of a T2A peptide and truncated mouse MHC class 
I molecule H-2Kk was amplified from plasmid pMACS-Kk.II (Miltenyi Biotec) using the primers Ck1 
(CTCTCGGCATGGACGAGCTGTACAAGAGGGCAAAGAGGGAGGGCAGAGGAAGTCTTCTA-
ACATGCGGTGACGTGGAGGAGAATCCCGGCCCTATGGCACCCTGCATGCTGCTCC) and Ck2 
(CTAGAACTAGTGGATCTGCAacgcgtATTATCACCCTCCTTTTCCACCTGTGTTTC). Plasmid pCAG-
Cas9v2T2A-venus-bpA was generated by Gibson assembly using plasmid pCAG-Cas9v2-bpA (Ralf  Kühn lab), 
opened with SphI and MluI, and 2 PCR products for the insertion of a T2A peptide and Venus coding sequence 
downstream of Cas9 using the primer pairs CV1 (CCACCGTGCGGAAAGTGCTGAG)/CV2 (TCACCG-
CATGTTAGAAGACTTCCTCTGCCCTCCCTCTTT-GCCCTGTCCACTTTCCGCTTTTTCTTAG-
GATC) and CV3 (GAAGTCTTCTAACATGCGGTGACGTGGAG-GAGAATCCCGGCCCTATGGT-
GAGCAAGGGCGAGGAGC)/CV4 (CTTGTACAGCTCGTCCATGCCGA-GAG) together with an 
overlapping PCR product for the insertion of a polyA signal (bpA) derived from the bovine growth hormone 
gene using the primer pair CV5 (CGG-CATGGACGAGCTGTACAAGTGATAATacgcgtTGCAGATC-
CACTAGTTCTAGAGCTCGCTGATCAG)/CV6 (CCATAGAGCCCACCGCATCCCCAG). Plasmid 
pCAG-Cas9v2-bpA was generated by cloning of a synthetic Cas9 coding region in between the CAG pro-
moter and bpA region. The origi-nal BbsI site of the sgRNA scaffold of pU6chimRNA-CAG-Cas9-venus-
bpA_(oriA) (Addgene, 86986) had been previously exchanged to a BplI site for sgRNA cloning using annealed 
oligos oHE28 and oHE29 (Supplemental Table 2). HE_p4.1 served as backbone to clone ABE7.10_4.1. The 
TadA heterodimer and the first 247 bp of Cas9 (D10A) were amplified by PCR from pCMV-ABE7.10 (19) 
with primers containing homology arms for Gibson Assembly. HE_p4.1 was digested with PacI and BglII, 
which excise the first 247 bp of the Cas9 CDS. The insert was cloned into the digested HE_p4.1 backbone 
using Gibson Assembly mix (New England Biolabs) for 1 hour at 50°C. For cloning ABE7.10_3.1, the part of  
Cas9 from amino acid 848–1060 was exchanged for the corresponding part of eSpCas9(1.1) (25) from pCAG-
eCas9v2(848_1003_1060A)-bpA (Ralf  Kühn lab) using EcoRV and BsmI. For sgRNA cloning, ABE7.10_4.1/
ABE7.10_3.1 were digested with BplI, and oligos oHE55 and oHE56 (Supplemental Table 2) were annealed 
and ligated. Constructs were verified by Sanger sequencing.
iPSC transfection and sorting. iPSC were plated 1 day before transfection on culture vessels coated with 
hESC-grade Matrigel (Corning) at a density of 300,000 cells/9.5 cm2 in mTeSR1 medium containing 10 μM 
Y-27632 2HCl (Selleckchem). They were transfected using Lipofectamine Stem Transfection Reagent (Ther-
mo Fisher Scientific) following manufacturer’s instructions. Medium was replaced before transfection by fresh 
mTeSR1. Two days after transfection, cells were collected for FACS in PBS containing 50% mTeSR1 (Stemcell 
Technologies), 0.1 mM EDTA (Thermo Fisher Scientific), 10 μM Y-27632 2HCl (Selleckchem), and 100 μg/
mL Primocin (InvivoGen). Venus+ cells were sorted using a FACSAria cell sorter (BD Biosciences) (Supple-
mental Figure 5) and cultured in mTeSR1. Y-27632 2HCl (10 μM) was added to the medium for 2 day or until 
most iPSC colonies consisted of more than 5–6 cells. Primocin (100 μg/mL) was added to the culture medium 
for 2 days to prevent contamination.
Human primary MuSC transfection and sorting. Human primary MuSC were plated 1 day before transfection 
at a density of  55,000 cells/9.5 cm2 in Skeletal Muscle Cell Growth Medium (SMCGM, Provitro) and trans-
fected using Lipofectamine3000 (Thermo Fisher Scientific) following manufacturer’s instructions. SMCGM 
was exchanged after 1 day. Two days after transfection, cells were collected for FACS in PBS containing 50% 
SMCGM, 0.05 mM EDTA, and 100 μg/mL Primocin. Venus+ cells were sorted using a FACSAria Fusion 
cell sorter (BD Biosciences) (Supplemental Figure 5) and cultured in SMCGM. Primocin (100 μg/mL) was 
added to the culture medium for 2 days.
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Mutation genotyping and genomic editing analysis via EditR. gDNA was isolated using Agencourt AMPure XP 
beads (Beckman Coulter). Briefly, each sample was lysed in a heating block with AL-Buffer (QIAGEN) con-
taining 0.2 mg/mL Proteinase K (QIAGEN) for 10 minutes at 56°C. Twice the volume of prewarmed beads 
was added to each sample and mixed on a rotational wheel. Tubes were placed on a magnetic rack to separate 
the beads from the supernatant. Beads were washed twice with 80% ethanol, and bound DNA was eluted using 
FG3 buffer (QIAGEN). Primers oHE24 + oHE25 and oHE26 + oHE27 were used for SGCA exon 2 and 7 
amplification, respectively (Supplemental Table 2). PCR was performed using Q5 or Phusion High-Fidelity 
DNA Polymerase (New England Biolabs) and cleanup of PCR products was done with a NucleoSpin Gel and 
PCR Clean-up kit (Macherey-Nagel). Sequence chromatograms were analyzed with EditR (24).
Off-target prediction. We used CRISPOR (53) for off-target prediction. A total of  70 off-target sites is pre-
dicted for gRNA#1 with SpCas9 (regardless of  whether they contain adenines within the ABE activity win-
dow). Only 1 (the WT SGCA exon 2 allele) has a single mismatch to the target site, while 3 and 65 sites have, 
respectively, 3 or 4 mismatches. Of those sites, only 1 contains 3 mismatches located outside the protospacer 
seed sequence. Most predicted sites are intronic or intergenic, with only 7 sites located in exons. We chose 
the 4 predicted exonic off-target sites containing adenines within the ABE activity window (protospacer 
positions 4–8) for further analysis.
Amplicon sequencing. Genomic DNA was isolated as described above. The following primers (Supplemen-
tal Table 2) were used for the first PCR amplification step: oHE255 + oHE256 (SGCA), oHE243 + oHE259 
(ZNF571), oHE260 + oHE246 (KIF1A), oHE261 + oHE248 (C1orf86/FAAP20), oHE249 + oHE262 (AJAP1). 
Following gel extraction, 20 ng of  product from the first amplification step was used for a second amplifica-
tion step with the same forward and reverse primers as before but containing Illumina adaptor sequences as 5′ 
overhangs (oHE263-oHE272; Supplemental Table 2). PCR bands were gel extracted, and the DNA concen-
tration was measured using a Qubit fluorometer (Thermo Fisher Scientific). The purity and size of  all PCR 
amplicons was assessed using a 2100 Bioanalyzer system and a DNA 1000 Kit (Agilent). All PCRs were per-
formed using Q5 High-Fidelity DNA Polymerase (New England Biolabs) and cleanup of  PCR products was 
done as above. Amplicon sequencing was performed by GENEWIZ (Amplicon EZ; GENEWIZ Germany 
GmbH) using an Illumina MiSeq platform with a 2 × 250 bp paired-end read configuration. For KIF1A, the 
PCR amplicon from the first amplification step was submitted to GENEWIZ. Raw sequencing data are avail-
able at the NCBI Sequence Read Archive (SRA) under the Bioproject accession no. PRJNA715491 (https://
www.ncbi.nlm.nih.gov/sra/PRJNA715491). Amplicon sequencing results were analyzed using CRISPRes-
so2 (26) with the following parameters: Editing tool: Base editors; Sequencing design: Paired end reads; Min-
imum homology for alignment to an amplicon: 60%; Base editor output: A>G; Center of  the quantification 
window (relative to 3′ end of  the provided sgRNA): –10; Quantification window size (bp): 10; Minimum 
average read quality (phred33 scale): >30; Minimum single bp quality (phred33 scale): No filter; Replace bas-
es with N that have a quality lower than (phred33 scale): No filter; Exclude bp from the left side of  the ampl-
icon sequence for the quantification of  the mutations: 15 bp; Exclude bp from the right side of  the amplicon 
sequence for the quantification of  the mutations: 15 bp.
RT-PCR and qPCR. Total RNA was isolated from muscle tissue sections or cultured cells with TRIzol fol-
lowing standard procedures. For RNA isolation from tissue, 1 mL TRIzol was added to 6 × 50 μm cryosections 
from human muscle biopsies. The suspension was then transferred to 2 mL DNase/RNase free Precellys lysing 
kit tubes with CK28-R matrix (Bertin Instruments) and homogenized twice for 20 seconds at 6800 rpm using a 
Precellys homogenizer (Bertin Instruments) before downstream processing for RNA extraction. cDNA synthe-
sis was performed using the QuantiTect Reverse Transcription kit (Qiagen). Q5 High-Fidelity DNA polymerase 
(New England Biolabs) was used for RT-PCR with primers oHE206-238 (Supplemental Table 2). Cleanup 
of PCR products was done as above. Relative mRNA levels were quantified via dye-based quantitative PCR 
(qPCR) in a CFX Connect Real-Time System (Bio-Rad) with primers oHE208-209 and oAK19-31 (Supplemen-
tal Table 2). All experiments were performed using KAPA SYBR FAST qPCR Master Mix Universal (Kapa 
Biosystems). Data were evaluated with the 2–ΔΔCT method. GAPDH was used as reference gene. qPCR results 
were analyzed with Bio-Rad CFX Maestro (v4.1).
Western blot. Samples were lysed on ice with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% Tri-
ton-X100, 0.5% sodium deoxycholate, 1 mM EDTA, 50 mM sodium fluoride, and 1 mM sodium orthova-
nadate) containing protease inhibitors. Protein concentration was determined using BCA Protein Assay Kit 
(Thermo Fisher Scientific). For each sample, 20 μg protein diluted in sample buffer (350 mM Tris–HCl, 30% 
glycerol, 10% sodium dodecyl sulfate, 600 mM DTT, and 0.05% bromophenol blue) were loaded onto a 
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8%–16% gradient Tris–glycine acrylamide gel (Thermo Fisher Scientific). Blocking was performed with 4% 
milk powder. Primary antibodies (Supplemental Table 4) were incubated overnight at 4°C, and HRP-conjugat-
ed secondary antibodies were incubated at room temperature for 45 minutes. The membrane was incubated 
with ECL reagent (Thermo Fisher Scientific) and imaged using a VWR CHEMI only system (VWR Interna-
tional GmbH). Images were processed using Adobe Photoshop CS5. Any adaptations were applied to the full 
image with all lanes. Quantification was performed with ImageJ (NIH).
Human MuSC transplantation. SGCA c.157Grep patient MuSC that were 99% Desmin+, 27% Pax7+, 25% 
Ki-67+, 66% MyoD+, and 40% Myf5+ were used for transplantation. Six-week-old male NOD.Cg-PrkdcscidIl-
2rgtm1WjI/SzJ (NSG) mice were purchased from Charles River Laboratories 1 week before the experiment. 
Animal housing and hygienic monitoring followed FELASA recommendations. Focal irradiation of  the 
recipient hind limbs was performed 2 days prior to cell transplantation as described (17, 18). Two injections 
of  5.5 μL containing 2.5 × 104 cells in a sterile PBS + 2% FCS solution were performed following parallel 
trajectories into the medial portion of  the anterior tibial (TA) muscle (in total, 5 × 104 cells per grafted mus-
cle) as described (18). Mice were sacrificed 19 days after cell transplantation. TA muscles were cryopreserved 
in liquid nitrogen–chilled isopentane, mounted in gum tragacanth, and stored at –80°C.
Immunostaining. Cells cultured on μ-Slides (8-well, ibidi) were fixed with 3.7% formaldehyde, permeabilized 
with 0.2% Triton X-100, and blocked in 5% bovine serum albumin (BSA)/PBS for 1 hour at room temperature. 
Muscle cryosections (6-μm) were cut with a Leica cryostat (CM3050 S). For human-specific Lamin A/C 
and Spectrin immunostaining, sections were fixed in acetone for 5 minutes at –20°C and blocked with 5% 
BSA/3% goat serum/PBS for 1 hour at room temperature. For huLaminA/C/Pax7/Laminin-DL488 immu-
nostaining, sections were fixed for 10 minutes at room temperature in 3.7% formaldehyde/PBS, permea-
bilized with 0.2% Triton-X/PBS for 5 minutes at room temperature, and blocked with 1% BSA/PBS for 1 
hour at room temperature. For huSpectrin/α-sarcoglycan immunostaining, sections were fixed in acetone 
for 5 minutes at –20°C and blocked with 5% BSA/3% goat serum/PBS for 1 hour at room temperature. For 
huLamin A/C and Desmin immunostaining, sections were fixed for 10 minutes at room temperature in 3.7% 
formaldehyde/PBS, permeabilized with 0.2% Triton-X/PBS for 5 minutes at room temperature, and blocked 
with 1% BSA/PBS for 1 hour at room temperature. Cultured cells or muscle cryosections were incubated 
overnight at 4°C with primary antibodies as indicated (Supplemental Table 4). AlexaFluor 488– or AlexaFlu-
or 568–conjugated secondary antibodies (Thermo Fisher Scientific) were incubated for 2 hours at room tem-
perature. Nuclei were counterstained with Hoechst 33258 (0.5 μg/mL, Sigma-Aldrich). Samples were imaged 
with a Zeiss LSM 700 confocal microscope (Carl Zeiss MicroImaging GmbH) or with a Leica DMI 6000 
fluorescence microscope (Leica Microsystem). Confocal images were composed and edited in ZEN 2.3 (Carl 
Zeiss Microscopy GmbH) and Adobe Illustrator. For the counting of  myogenic and proliferation markers, at 
least 100 nuclei per sample were counted.
Statistics. Details about the statistical tests are described in the corresponding figure legend. Graphs show the 
mean ± SD where applicable. Group sizes and a description of the represented values and error bars for each 
figure are indicated in the corresponding figure legend. No samples were excluded from the analysis.
Study approval. Research use of human material was approved by the regulatory agencies (EA2/051/10 and 
EA2/175/17, Charité Universitätsmedizin Berlin), and written informed consent was obtained from donors or 
legal guardians. Animal experiments were performed under the license number G 0058/20 (LaGeSo).
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